William Wood
Stock Analyst at B. Riley Securities
(3.60)
# 2,063
Out of 4,689 analysts
55
Total ratings
52.1%
Success rate
10%
Average return
Main Sectors:
Stocks Rated by William Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACOG Alpha Cognition | Initiated Coverage: Buy | $21 | $9.16 | +129.26% | 1 | Aug 20, 2026 | |
| TGTX TG Therapeutics | Maintained: Buy | $55 → $86 | $53.93 | +59.47% | 2 | Jul 27, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiated Coverage: Buy | $34 | $13.17 | +158.16% | 1 | Jul 23, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $31 | $16.79 | +84.63% | 1 | Jul 17, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | $85 | $32.16 | +164.30% | 1 | Jun 25, 2026 | |
| PALI Palisade Bio | Reiterated: Buy | $7 | $2.00 | +250.00% | 2 | Jun 2, 2026 | |
| EQ Equillium | Reiterated: Buy | $6 | $2.39 | +151.05% | 2 | Jun 2, 2026 | |
| IMUX Immunic | Maintained: Buy | $50 → $27 | $15.40 | +75.32% | 10 | May 22, 2026 | |
| AARD Aardvark Therapeutics | Maintained: Buy | $8 → $7 | $5.79 | +20.90% | 3 | May 15, 2026 | |
| ALT Altimmune | Maintained: Buy | $13 | $3.11 | +318.01% | 1 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $560 → $670 | $533.76 | +25.52% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $1.67 | +199.40% | 1 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 | $1.02 | +194.12% | 1 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $2.63 | n/a | 7 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $11 | $3.14 | n/a | 10 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $15.55 | n/a | 5 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $3.23 | n/a | 4 | May 2, 2024 |
Alpha Cognition
Aug 20, 2026
Initiated Coverage: Buy
Price Target: $21
Current: $9.16
Upside: +129.26%
TG Therapeutics
Jul 27, 2026
Maintained: Buy
Price Target: $55 → $86
Current: $53.93
Upside: +59.47%
AgomAb Therapeutics NV
Jul 23, 2026
Initiated Coverage: Buy
Price Target: $34
Current: $13.17
Upside: +158.16%
Trevi Therapeutics
Jul 17, 2026
Reiterated: Buy
Price Target: $31
Current: $16.79
Upside: +84.63%
Viking Therapeutics
Jun 25, 2026
Reiterated: Buy
Price Target: $85
Current: $32.16
Upside: +164.30%
Palisade Bio
Jun 2, 2026
Reiterated: Buy
Price Target: $7
Current: $2.00
Upside: +250.00%
Equillium
Jun 2, 2026
Reiterated: Buy
Price Target: $6
Current: $2.39
Upside: +151.05%
Immunic
May 22, 2026
Maintained: Buy
Price Target: $50 → $27
Current: $15.40
Upside: +75.32%
Aardvark Therapeutics
May 15, 2026
Maintained: Buy
Price Target: $8 → $7
Current: $5.79
Upside: +20.90%
Altimmune
Mar 6, 2026
Maintained: Buy
Price Target: $13
Current: $3.11
Upside: +318.01%
Dec 11, 2025
Maintained: Buy
Price Target: $560 → $670
Current: $533.76
Upside: +25.52%
Dec 8, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $1.67
Upside: +199.40%
Nov 21, 2025
Maintained: Buy
Price Target: $3
Current: $1.02
Upside: +194.12%
Feb 11, 2025
Reiterated: Buy
Price Target: $50
Current: $2.63
Upside: n/a
Aug 8, 2024
Maintained: Buy
Price Target: $12 → $11
Current: $3.14
Upside: n/a
May 8, 2024
Reiterated: Buy
Price Target: $10
Current: $15.55
Upside: n/a
May 2, 2024
Maintained: Buy
Price Target: $4
Current: $3.23
Upside: n/a